Welcome to the new ProRhythm!
Since
1997, ProRhythm has been known as Transurgical. Beginning with
our inception, we have pioneered the application of High
Intensity Focused Ultrasound (HIFU) to advance the minimally
invasive treatment
of complex medical conditions.
In
recent years, we have concentrated our efforts on the development
of HIFU for the treatment of a debilitating arrhythmia, Atrial
Fibrillation (AF). AF is an uncontrollable, rapid, heartbeat,
which can result in a significant decline in one’s quality
of life and can lead to significant, life threatening complications.
Globally,
approximately 8 million people are afflicted with AF and the
current treatment options are often inadequate.
As
our focus has shifted to the treatment of AF, we have found that
the name “Transurgical” no longer represents our
core business and in many instances has been confusing to
our key customers.
In order to more accurately reflect our core business and
to communicate our goal of restoring patients with Atrial
Fibrillation
to their
normal heart beat, sinus rhythm, on May 19, 2004, Transurgical
changed it’s name to ProRhythm, Inc.
The
expertise of countless cardiac electrophysiologists has been
applied to find a way to treat AF through a technique
known as
cardiac ablation. While demonstrating that ablation of
cardiac tissue can effectively treat Atrial Fibrillation,
current
technology has limited the overall success and therefore,
the adoption
of the procedure.
ProRhythm’s
HIFU technology is currently being used today to treat AF in
clinical trials in Europe and the United States
to treat AF. We are excited as we believe that our technology
can play a significant role in the treatment of this disease
and help
to improve the lives of countless individuals who are
afflicted with Atrial Fibrillation.
I
invite you to explore our website and learn more about how this
exciting technology is being applied to the
treatment of this disease.
Sincerely,
Reinhard Warnking
President and CEO
|
